Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Gliatech Inc.

This article was originally published in The Gray Sheet

Executive Summary

Gliatech Inc.: Reports results of two clinical studies demonstrating the clinical effectiveness of the firm's Adcon-L and Adcon-T/N resorbable, barrier gels in "inhibiting postoperative adhesions and improving surgical outcome." Presented the week of Aug. 18 at the International Society of Orthopedic and Trauma Surgeons World Congress in Amsterdam, one study of 267 first-time lumbar discetomy patients shows that Adcon-L "significantly decreased peridural scar and improved patient outcome by reducing the incidence of activity related pain while performing typical activities of daily living." In a study involving 32 hand tenolysis procedures, patients treated with Adcon-T/N "showed a 118% greater improvement in digital range of motion compared to controls." Gliatech has clinical trials ongoing in the U.S. for the two gel-based products...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel